<DOC>
	<DOCNO>NCT00675350</DOCNO>
	<brief_summary>PK Study Homoharringtonine ( Omacetaxine Mepesuccinate ) Administered Subcutaneously Patients With Advanced Solid Hematologic Tumors</brief_summary>
	<brief_title>Pharmacokinetic ( PK ) Study Homoharringtonine ( Omacetaxine Mepesuccinate ) Administered Subcutaneously Patients With Advanced Solid Hematologic Tumors</brief_title>
	<detailed_description>This open-label non-randomized pharmacokinetic ( PK ) study Homoharringtonine ( Omacetaxine Mepesuccinate ) administer subcutaneous ( SC ) injection patient relapse and/or refractory hematologic malignancy patient advance solid tumor bone marrow involvement .</detailed_description>
	<mesh_term>Homoharringtonine</mesh_term>
	<mesh_term>Harringtonines</mesh_term>
	<criteria>Be ≥18 year old . Be diagnose relapsed refractory leukemia include chronic myelogenous leukemia ( CML ) , acute promyelocytic leukemia ( APL ) , acute myelogenous leukemia ( AML ) , myelodysplastic syndrome ( MDS ) Relapsed define reappearance leukemic blast peripheral blood find ≥5 % blast bone marrow , attributable another cause ( e.g. , bone marrow regeneration consolidation therapy ) . Refractory define response previous combine chemotherapy regimens include least one cytarabine plus one anthracycline advance solid tumor ( i.e. , breast , lung , head / neck , colorectal , melanoma , sarcoma ) . Patients must exhaust become intolerant available therapy . ( Patients hematologic malignancy ) : Have complete previous antileukemic therapy ( except leukapheresis ) least 2 week prior first plan dose OMA must fully recover side effect previous therapy unless , disease progression necessitate early therapy . Leukapheresis allow 24 hour prior registration . ( Patients solid tumor ) : Patients may measurable unmeasurable disease . Measurable disease define least one lesion accurately measure least one dimension ( long diameter record ) ≥20 mm conventional computerize tomography ( CT ) magnetic resonance imaging ( MRI ) scan , ≥10 mm spiral computerize tomography ( CT ) scan . Imaging must perform within 28 day first dose study drug . Have estimate life expectancy ≥12 week Have Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤2 ( see Appendix B ) Be able provide write informed consent prior enrollment study . In event patient rescreened study participation protocol amendment alters care ongoing patient , new inform consent form must sign . Be male nonpregnant , nonlactating female . Fertile patient must agree use effective barrier method contraception ( e.g. , latex condom , diaphragm , cervical cap ) avoid pregnancy therapy 6 month follow discontinuation study drug . A nonfertile female define : Postmenopausal ( amenorrheic ≥12 month ) Undergone complete oophorectomy hysterectomy . Have negative serum pregnancy test within 7 day prior first dose study drug ( patient female childbearing potential ) . QTc &lt; 450 m screen 12lead ECG ( use Bazett 's correction QT interval formula [ QTcB ] ) . Have adequate organ function indicate follow laboratory value obtain within 7 day prior first dose study drug outline Table 3 . Be able willing comply requirement entire study . Received previous treatment OMA within 6 month study entry . Have New York Heart Association ( NYHA ) Class 3 4 heart disease , active ischemia , uncontrolled , unstable cardiac condition treatment condition indicate control despite adequate therapy , include angina pectoris , cardiac arrhythmia , hypertension , congestive heart failure ( see Appendix D ) . Experienced myocardial infarction previous 12 week . Have solid tumor know bone marrow central nervous system ( CNS ) involvement . Have active , uncontrolled systemic infection consider opportunistic , life threatening , clinically significant time treatment . Are pregnant lactating . Received systemic chemotherapy 4 week prior first dose study drug , unless treatment require progressive leukemia . In patient rapidly proliferate disease , hydroxyurea may administer immediately prior first two cycle treatment , clinically indicate , control disease . Received radiation therapy within 6 week first dose study drug . Localized radiation palliation may administer 2 week first dose study drug . Have medical condition psychiatric disorder ( ) render patient unable understand nature , scope , possible consequence study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Omacetaxine</keyword>
	<keyword>Homoharringtonine</keyword>
	<keyword>HHT</keyword>
	<keyword>Solid hematologic malignant tumor</keyword>
</DOC>